Marvel Biosciences Selects Adelaide Site for Planned MB-204 Phase I Study
Marvel Biosciences selected CMAX in Adelaide, Australia, as the site for its planned first-in-human study of MB-204. The study is subject to regulatory and ethics approvals.
Marvel Biosciences selected CMAX in Adelaide, Australia, as the site for its planned first-in-human study of MB-204. The study is subject to regulatory and ethics approvals.